Markets

Solid tumor and blood cancer biotech TCR2 Therapeutics files for a $100 million IPO

TCR2 Therapeutics, a preclinical biotech developing immunotherapies for solid tumors and blood cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol TCRR. TCR2 Therapeutics filed confidentially on September 7, 2018. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Solid tumor and blood cancer biotech TCR2 Therapeutics files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More